Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas

Natthapol Songdej, Eric S. Winer

Research output: Chapter in Book/Report/Conference proceedingChapter


Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.

Original languageEnglish (US)
Title of host publicationNon-Hodgkin Lymphoma
Subtitle of host publicationPrognostic Factors and Targets
PublisherSpringer New York
Number of pages20
ISBN (Electronic)9781461458517
ISBN (Print)9781461458500
StatePublished - Jan 1 2013

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas'. Together they form a unique fingerprint.

Cite this